Published online July 1, 2005
PEDIATRICS Vol. 116 No. 1 July 2005, pp. 195-204 (doi:10.1542/10.1542/peds.2005-0074)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leslie, L. K.
Right arrow Articles by Perrin, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leslie, L. K.
Right arrow Articles by Perrin, J. M.
Related Collections
Right arrow Therapeutics & Toxicology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

SPECIAL ARTICLE

The Food and Drug Administration’s Deliberations on Antidepressant Use in Pediatric Patients

Laurel K. Leslie, MD*, Thomas B. Newman, MD, MPH{ddagger}, P. Joan Chesney, MD§ and James M. Perrin, MD||

* Children’s Hospital, Child and Adolescent Services Research Center, San Diego, California
{ddagger} Departments of Epidemiology and Biostatistics and Pediatrics, University of California, San Francisco, California
§ Department off Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee
|| MGH Center for Child and Adolescent Health Policy, Harvard Medical School, Boston, Massachusetts

On February 2, 2004, the Food and Drug Administration organized a joint meeting of the Neuro-Psychopharmacologic Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee to examine the occurrence of suicidality in clinical trials that investigate the use of the newer antidepressant drugs in pediatric patients. Committee members reconvened on September 13–14, 2004, and concluded that there was a causal link between the newer antidepressants and pediatric suicidality. This article provides a summary of the Food and Drug Administration deliberations for the pediatric clinician. We also provide research, regulation, education, and practice implications for care for children and adolescents who may be eligible for treatment with these medications.

Key Words: depression • pediatrics • children • adolescents • antidepressants • suicide • regulation • mental health • FDA

Abbreviations: FDA, Food and Drug Administration • MDD, major depressive disorder • DD, dysthymic disorder • BPD, bipolar disorder • CBT, cognitive behavioral therapy • SSRI, selective serotonin reuptake inhibitor • FDAMA, Food and Drug Administration Modernization Act • BPCA, Best Pharmaceuticals for Children Act • MHRA, Medicines and Healthcare Products Regulatory Agency • TADS, Treatment for Adolescents With Depression Study

Accepted Mar 30, 2005.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
A. Heneghan, A. S. Garner, A. Storfer-Isser, K. Kortepeter, R. E. K. Stein, and S. McCue Horwitz
Use of Selective Serotonin Reuptake Inhibitors by Pediatricians: Comparing Attitudes of Primary Care Pediatricians and Child and Adolescent Psychiatrists
Clinical Pediatrics, March 1, 2008; 47(2): 148 - 154.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
A. Pakalnis
Current Therapies in Childhood and Adolescent Migraine
J Child Neurol, November 1, 2007; 22(11): 1288 - 1292.
[Abstract] [PDF]

Home page
 Am. J. PsychiatryHome page
C. R. Pfeffer
The FDA Pediatric Advisories and Changes in Diagnosis and Treatment of Pediatric Depression
Am J Psychiatry, June 1, 2007; 164(6): 843 - 846.
[Full Text] [PDF]

Home page
 Clin TrialsHome page
E. E Kaizar, J. B Greenhouse, H. Seltman, and K. Kelleher
Do antidepressants cause suicidality in children? A Bayesian meta-analysis
Clinical Trials, April 1, 2006; 3(2): 73 - 98.
[Abstract] [PDF]

Home page
 AAP Grand RoundsHome page
A. Schonwald
Do Antidepressants Increase Suicide Risk?
AAP Grand Rounds, April 1, 2006; 15(4): 49 - 50.
[Full Text] [PDF]

Home page
 PediatricsHome page
J. B. Greenhouse and K. J. Kelleher
Thinking Outside the (Black) Box: Antidepressants, Suicidality, and Research Synthesis
Pediatrics, July 1, 2005; 116(1): 231 - 233.
[Full Text] [PDF]

Home page
 PediatricsHome page
L. M. Wegner
Pediatricians and Antidepressant Medications: Black Box or Black Hole?
Pediatrics, July 1, 2005; 116(1): 233 - 235.
[Full Text] [PDF]